A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with Patisiran

Trial Profile

A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with Patisiran

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Patisiran (Primary)
  • Indications Amyloid polyneuropathy
  • Focus Adverse reactions
  • Acronyms APOLLO-OLE
  • Sponsors Alnylam Pharmaceuticals
  • Most Recent Events

    • 26 Apr 2017 Eligible patients (n = 25) who completed the phase II open-label trial enrolled in the APOLLO-OLE study; 20 have received at least 36 months of dosing as of April 12, 2017. 36-month data from this cohort of patients is expected in late 2017, according to an Alnylam Pharmaceuticals media release.
    • 31 Jul 2015 Planned End Date changed from 20 Jul 2020 to 1 Jan 2018.
    • 31 Jul 2015 Planned primary completion date changed from 20 Jul 2020 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top